Evidence map›Paper›PMID 30511011›Full record

ArticleAlzheimer's & dementia (New York, N. Y.)2018

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.

Brian A Willis, Karen Sundell, D Richard Lachno, Lisa R Ferguson-Sells, Michael G Case, Karen Holdridge, Ronald B DeMattos, Joel Raskin, Eric R Siemers, Robert A Dean

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia (New York, N. Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Brian A WillisEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Karen SundellEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
D Richard LachnoEli Lilly and Company, Windlesham, UK.
Lisa R Ferguson-SellsEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Michael G CaseEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Karen HoldridgeEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Ronald B DeMattosEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Joel RaskinEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Eric R SiemersEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Robert A DeanEli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA.
Eli Lilly (United States) · USEli Lilly (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSolanezumab treatment was previously shown to significantly increase total (bound + unbound) cerebrospinal fluid (CSF) levels of amyloid β (Aβ)

methodsCSF Aβ isoform concentrations were measured in patients with mild Alzheimer's disease dementia from a pooled EXPEDITION + EXPEDITION2 population and from EXPEDITION3. CSF solanezumab concentrations were determined from EXPEDITION3.

resultsSolanezumab produced statistically significant increases in CSF total Aβ isoforms versus placebo, which correlated with CSF solanezumab concentration. Inconsistent effects on free Aβ isoforms were observed. Solanezumab penetration into the central nervous system was low. DISCUSSION: Solanezumab administration engaged the central molecular target, and molar ratio analyses demonstrated that higher exposures may further increase CSF total Aβ concentrations.

Indexed as

Alzheimer's diseaseBiomarkersCerebrospinal fluidPharmacodynamicsSolanezumab

Identifiers

PMID30511011
PMCPMC6258891
OpenAlexW2900308507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.